Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and/or senescent cells. The donor quiescent and/or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and/or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ε-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

A disposable absorbent hygiene product is provided, comprising an absorbent core disposed between a liquid pervious topsheet intended to face the wearer, and a backsheet intended to face away from the wearer, wherein said absorbent core comprises a super absorbent polymer composition that comprises a) super absorbent polymer particles including a cross-linked polymer of a water soluble ethylenically unsaturated monomer containing an acidic group, at least a part of said acidic groups being neutralized; and b) a particle size-controlled antibacterial agent that comprises a chelating agent containing EDTA or an alkali metal salt thereof; a mixture of an organic acid and a silicate-based salt; and a particle size control agent.

One aspect of the present disclosure can include a thermoresponsive nanocomposite for disrupting or preventing biofilm formation. The nanocomposite can include at least one polymer, one or more D-amino acids, and one or more energy-actuatable particles. The nanocomposite can have a first viscosity at about room temperature and, when exposed to about physiological temperature, obtains a second viscosity that is greater than the first viscosity. Application of energy to the nanocomposite from an energy source can excite the one or more energy-actuatable particles to cause localized heat release from the nanocomposite.

This invention is directed to novel compositions containing a source of precursors to Type I collagen, an collagenic organic acid, an aldehyde, a polyol, an aldose, esters or salts or any combinations thereof, a blend of collagenic monomers or short-chain polymers, and a thickening agent to optimize the viscosity of the delivery system and methods of using such compositions for promoting collagen synthesis in the annular region of intervertebral disc.

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

A method includes identifying a subject as having a pathological Central Nervous System (CNS) condition; and, in response, implanting, at a CNS site of the subject, a piece of a hydrogel (50). The hydrogel may be a polypseudorotaxane hydrogel. The polypseudorotaxane hydrogel may include crosslinked axles of a polymer. The polymer may include ethylene oxide (EO). The polypseudorotaxane hydrogel may further include molecules of a cyclodextrin, threaded onto the axles. Other embodiments are also described.

The disclosure provides a preparation method for a novel biocompatible antibacterial bacterial cellulose Fmoc-F hydrogel, belonging to the technical field of biomedical gels. The preparation method is characterized by comprising the following steps of (1) preparing a bacterial cellulose (BC) homogenate, (2) mixing the bacterial cellulose with an Fmoc-F solution, and preparing the bacterial cellulose/Fmoc-F antibacterial hydrogel by means of in-situ chemical crosslinking. The preparation method has the advantages of rapid gelling reaction, simple reaction system, high gel plasticity and the like. Because of the bacterial cellulose, the antibacterial hydrogel prepared in the disclosure has high mechanical strength. Meanwhile, compared with traditional micro-molecular antibacterial materials, the bacterial cellulose/Fmoc-F antibacterial hydrogels prepared in the disclosure have broad-spectrum antibacterial effects and good biocompatibility.